IXICO (IXI) Competitors GBX 9.90 +0.15 (+1.54%) As of 07/11/2025 06:42 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock IXI vs. SBTX, COS, C4XD, DDDD, TRX, SAR, FUM, OKYO, AOR, and ARECShould you be buying IXICO stock or one of its competitors? The main competitors of IXICO include SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Tissue Regenix Group (TRX), Sareum (SAR), Futura Medical (FUM), OKYO Pharma (OKYO), AorTech International (AOR), and Arecor Therapeutics (AREC). These companies are all part of the "biotechnology" industry. IXICO vs. Its Competitors SkinBioTherapeutics Collagen Solutions plc (COS.L) C4X Discovery 4D pharma Tissue Regenix Group Sareum Futura Medical OKYO Pharma AorTech International Arecor Therapeutics SkinBioTherapeutics (LON:SBTX) and IXICO (LON:IXI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Which has preferable valuation & earnings, SBTX or IXI? IXICO has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSkinBioTherapeutics£1.56M24.59-£3.71M-£1.63-10.33IXICO£11.50M0.80-£3.58M-£3.86-2.57 Does the media refer more to SBTX or IXI? In the previous week, SkinBioTherapeutics' average media sentiment score of 0.00 equaled IXICO'saverage media sentiment score. Company Overall Sentiment SkinBioTherapeutics Neutral IXICO Neutral Which has more risk and volatility, SBTX or IXI? SkinBioTherapeutics has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500. Comparatively, IXICO has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Do institutionals & insiders believe in SBTX or IXI? 16.6% of SkinBioTherapeutics shares are owned by institutional investors. Comparatively, 56.0% of IXICO shares are owned by institutional investors. 20.4% of SkinBioTherapeutics shares are owned by company insiders. Comparatively, 30.3% of IXICO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is SBTX or IXI more profitable? IXICO has a net margin of -31.10% compared to SkinBioTherapeutics' net margin of -237.95%. IXICO's return on equity of -19.14% beat SkinBioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SkinBioTherapeutics-237.95% -115.86% -61.18% IXICO -31.10%-19.14%-10.40% SummaryIXICO beats SkinBioTherapeutics on 8 of the 11 factors compared between the two stocks. Get IXICO News Delivered to You Automatically Sign up to receive the latest news and ratings for IXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IXI vs. The Competition Export to ExcelMetricIXICOBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£9.17M£129.37M£5.61B£3.00BDividend Yield1.27%3.74%5.24%5.02%P/E Ratio-2.573.4727.96150.91Price / Sales0.804,141.03430.89314,545.51Price / Cash2.2513.1937.4627.97Price / Book0.5142.088.044.59Net Income-£3.58M-£92.15M£3.18B£5.90B7 Day Performance1.54%1.27%3.68%11.51%1 Month Performance-17.50%4.30%4.10%7.90%1 Year Performance41.43%174.69%29.59%32.03% IXICO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IXIIXICON/AGBX 9.90+1.5%N/A+46.7%£9.17M£11.50M-2.5789SBTXSkinBioTherapeuticsN/AGBX 16.50flatN/A+86.7%£37.69M£1.56M-10.1511High Trading VolumeCOSCollagen Solutions plc (COS.L)N/AN/AN/AN/A£30.99M£4.01M-8.283,350C4XDC4X DiscoveryN/AN/AN/AN/A£30.27M£24.68M300.0049High Trading VolumeDDDD4D pharmaN/AN/AN/AN/A£30.05M£718K-1.08106TRXTissue Regenix GroupN/AGBX 28.60+0.4%N/A-60.2%£25.78M£31.98M-29.53120SARSareumN/AGBX 19.75+1.3%N/A-46.9%£24.67MN/A-4.683,211FUMFutura MedicalN/AGBX 7.88+5.8%N/A-67.6%£24.56M£8.68M-6.5012Gap UpOKYOOKYO PharmaN/AN/AN/AN/A£23.24MN/A-140.007Gap DownAORAorTech InternationalN/AN/AN/AN/A£19.99M£539K-33.383ARECArecor TherapeuticsN/AGBX 43.17-0.8%N/A-55.8%£16.30M£6.04M-1.5310High Trading Volume Related Companies and Tools Related Companies SBTX Competitors COS Competitors C4XD Competitors DDDD Competitors TRX Competitors SAR Competitors FUM Competitors OKYO Competitors AOR Competitors AREC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:IXI) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored"I'm risking my reputation on this"Most people think you need thousands to profit from crypto. But this free book exposes how even small inves...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IXICO plc Please log in to your account or sign up in order to add this asset to your watchlist. Share IXICO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
